Dogma Biotech
Bogotá, Colombia· Est.
Colombian biotech pioneering RNA‑targeted therapies for oncology and rare diseases with an early‑stage pipeline.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $12M
AI Company Overview
Colombian biotech pioneering RNA‑targeted therapies for oncology and rare diseases with an early‑stage pipeline.
OncologyRare Diseases
Technology Platform
Proprietary RNA‑targeted and gene‑editing platform combining antisense oligonucleotides, siRNA, and CRISPR technologies for precise modulation of disease‑causing transcripts.
Opportunities
Strategic partnerships with global pharma and successful IND filings could accelerate development and provide access to larger markets.
Risk Factors
Limited funding resources, regulatory hurdles, and the need to build manufacturing capabilities for RNA therapeutics pose significant risks.
Competitive Landscape
Few companies in Latin America focus on RNA‑based oncology and rare disease therapies, giving Dogma a differentiation advantage but also exposing it to competition from larger global biotech firms.